Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Integrating Multicancer Early Detection into Clinical Care



ReachMD Healthcare Image

Explore key considerations for incorporating a liquid biopsy for multi-cancer early detection into practice.

  • Sponsored by

  • Overview

    The last five years have seen exciting progress with liquid biopsy tests, with one of them being a screening tool for multi-cancer early detection that looks for methylation patterns that can detect more cancers earlier, even before symptoms appear.1,2 Learn how you can incorporate this screening tool into clinical practice with Drs. Sana Raoof, Candace Westgate, and Mylynda Massart. Dr. Raoof is a physician scientist at Memorial Sloan Kettering Cancer Center, Dr. Westgate is the Medical Director of the AHEAD Program and Chief of Staff at Adventist Health Saint Helena in Northern California, and Dr. Massart is the Founder and Director of the UPMC’s Primary Care Precision Medicine Center.


    1. Nadauld LD, McDonnell CH 3rd, Beer TM, et al. The PATHFINDER Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice. Cancers (Basel). 2021;13(14):3501. Published 2021 Jul 13. doi:10.3390/cancers13143501
    2. Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-759. doi:10.1016/j.annonc.2020.02.011
  • Important Safety Information

    Important Safety Information
    The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

    Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “No Cancer Signal Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

    If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

    Laboratory/test information
    GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

Schedule28 May 2024